Jon henson (@Bezel4455) header
Jon henson (@Bezel4455) profile picture

30+ years riding the market waves 🌊. Full-time investor for 20 of those, now living the ticker life πŸ“ˆ. Tweets are ideas, not adviceβ€”always DYODD, folks!

Joined May 2022
Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)Photo by Jon henson (@Bezel4455)
$TGL one to watch Monday πŸ‘€πŸ”₯ 52-week range $2.04 - $58.00 That $58 high is real β€” $TGL exploded after its Dec. 2025 reverse split with massive momentum/volume before eventually getting crushed back down. Now around $2.50, sitting just off 52-week lows. πŸ”₯ Shares recently became accessible through Binance Stocks Trading, potentially expanding global exposure. πŸ’° Agreements to sell its V Gallant + Reveillon interests for $6.6M, bringing additional liquidity over 36 months. πŸ’» Recently signed $3M in software development agreements tied to its Lifestyle Membership & Experience Platform. After the brutal selloff, $TGL has already bounced roughly 24% off the $2.04 low. Former $58 momentum runner + near 52-week lows + fresh developments. If volume comes back, this one could get interesting FAST. $TGL on watch Monday πŸ‘€πŸ”₯
3
5
1,711
$VTGN πŸ‘€ πŸ”ΉοΈ Yesterday's multibillion-dollar Eli Lilly acquisition of AtaiBeckley $ATAI shows Big Pharma is willing to pay a premium for innovative intranasal CNS therapies. πŸ”ΉοΈ Vistagen's pipeline is also built around a proprietary intranasal pherine platform targeting brain neurocircuitry with rapid-onset, non-systemic treatments. πŸ”ΉοΈ Refisolone (PH80) is being developed as a non-hormonal treatment for menopausal hot flashes, a massive unmet market, and the company is also in discussions with Fuji Pharma regarding Japan. πŸ”ΉοΈ Different science and different indications than Lilly's acquisitionβ€”but today's deal highlights continued pharmaceutical interest in novel intranasal CNS technologies. πŸ”ΉοΈ If VTGN delivers positive clinical and partnership progress, it could become a company that larger pharmaceutical firms watch closely. πŸ‘€ One to keep on the radar. #VTGN #Biotech #Stocks #SmallCaps Not financial advice. For informational purposes only.
2
6
2,496
πŸš› $FRGT gaining momentum again, up 11% premarket. The story is starting to get noticed. πŸ”Ή Tiny tradable float can amplify moves when volume pours in. πŸ”Ή AI-powered cross-border logistics and freight tech remain the core growth narrative. πŸ”Ή If momentum continues and more traders discover the setup, I still believe $20+ is achievable over time. πŸ‘€ I'm holding and letting the thesis play out. Patience is often rewarded when the market finally catches on. Not financial advice. Do your own due diligence.
1
1
3
1,690
$ROLR πŸ‘€πŸ”₯ Trading just under $7 and looking like it wants another leg higher. πŸ”ΉοΈ The prediction markets story is gaining traction with regulatory approvals and the U.S. rollout continuing to advance. πŸ”ΉοΈ Recent addition to the Russell Microcap Index increases visibility and could help attract additional institutional interest. πŸ”ΉοΈ If buyers keep stepping in and volume expands, a break above the recent resistance could trigger another momentum move. πŸ”ΉοΈ Tight share structure and a hot sector make this one worth watching closely. Momentum names can move fast once key levels break. πŸ”ΉοΈ Watching for a clean breakout above $7. If that happens, I think traders will start targeting higher prices in a hurry. πŸ‘€ On watch. Could be just getting started. **Not financial advice. Do your own DD.**
1
1
2
1,729
$FRGT πŸ‘€πŸ”₯ Next $SDOT? Don't miss this one. πŸ”ΉοΈ AI transformation is accelerating as management shifts away from traditional freight brokerage toward a software-first, AI-powered logistics company. πŸ”ΉοΈ Cost-cutting and restructuring are designed to improve margins and position the business for long-term scalable growth. πŸ”ΉοΈ The market is still pricing FRGT like an old-school freight broker while the company continues executing its AI logistics strategy. πŸ”ΉοΈ Low float + growing AI narrative + improving business model = a combination that can attract momentum traders in a hurry. πŸ”ΉοΈ If this story continues to gain attention, I believe FRGT has the potential to become the next $SDOT-type runner. πŸ‘€ On my watchlist and still accumulating. **Not financial advice. Do your own DD.**
2
4
1,688
$FRGT πŸ‘€ This one is getting my attention again. πŸ’Ž Tiny tradable float of roughly 560K shares after multiple reverse splits makes it highly reactive to volume. πŸ’Ž Shares outstanding are approximately 5.5M, with very little institutional ownership. πŸ’Ž Company continues its transition toward an AI-powered logistics/software business while recently refinancing debt with a $2.5M term loan to strengthen its balance sheet. πŸ’Ž When micro-floats like this catch momentum, moves can be explosive. Volume is the key. Watching closely. πŸ‘€πŸš€ Not financial advice. Do your own DD.
3
4
1,340
🚨 $VTGN 🚨 πŸ’Ž Menopause is becoming one of healthcare's biggest untapped markets. Estimates are $15-25B+ by 2030, and many believe that's just the floor. πŸ’Ž Vistagen is developing refisolone (PH80) β€” a fast-acting investigational nasal spray designed for menopausal hot flashes. πŸ’Ž βœ… Non-hormonal πŸ’Ž βœ… Non-systemic πŸ’Ž βœ… Designed to work through nose-to-brain neurocircuitry in seconds. πŸ’Ž FDA has already issued a "Study May Proceed" letter for the U.S. Phase 2 trial. πŸ’Ž Investors are watching July 21 for potential news surrounding the Fuji Pharma partnership discussions. πŸ’Ž The recent selloff looks overdone to me. If management executes, this could become one of the more interesting women's health stories in biotech. πŸ‘€ Watching closely. Holding. Not financial advice. For informational purposes only.
1
1
5
2,162
$ELAB πŸš€πŸ‘€ πŸ”ΉοΈ PMGC continues expanding beyond biotech, building positions in aerospace, defense, space, and GLP-1-related technologies through multiple acquisitions and subsidiaries. πŸ”ΉοΈ Recent news includes the merger of its aerospace precision manufacturing businesses to streamline operations and improve efficiency while maintaining existing customer relationships. πŸ”ΉοΈ The company has also filed new patent applications targeting lean muscle preservation alongside GLP-1 therapies, a rapidly growing area of interest. πŸ”ΉοΈ Add in the defense, drone, and space manufacturing exposure, and this story has multiple sectors that continue to attract investor attention. πŸ”ΉοΈ If volume continues to build, this is one that could make a strong move. πŸ‘€πŸ”₯ #ELAB #Stocks #SmallCaps #Biotech #Defense Not financial advice. For informational purposes only.
2
4
1,699
$SRXH πŸš€ Loaded target $6+ πŸ”ΉοΈ Board of Directors has authorized a stock repurchase program to buy back up to 10 million shares, representing up to 50% of shares outstanding. πŸ”ΉοΈ Buybacks of this size can significantly reduce the public float while signaling management believes the stock is undervalued. πŸ”ΉοΈ Comes on the heels of the company reporting approximately $3.07 per share in preliminary NAV, over $55M in cash and short-term investments, and no debt. πŸ”ΉοΈ Definitely one to keep on watch. πŸ‘€ #SRXH #Stocks #SmallCaps #Momentum Not financial advice. For informational purposes only.
2
6
1,849
$OSTX πŸš€πŸ‘€ πŸ”ΉοΈ FDA accepted a new meeting request to review the company's patent-pending OST-HER2 biomarker data, another step toward a potential BLA submission. πŸ”ΉοΈ Type B FDA meetings with both CDER and CBER are expected as the company prepares for Accelerated Approval. πŸ”ΉοΈ Interim 3-year overall survival data is expected this summer, with a BLA submission targeted for early Fall 2026. πŸ”ΉοΈ OST-HER2 already holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations. πŸ”ΉοΈ If approved, OSTX expects to receive a Priority Review Voucher (PRV), which management intends to sell. Recent analyst estimates value a PRV around $180M, exceeding the company's current market cap. πŸ”ΉοΈ Roth Capital initiated coverage with a Buy rating and a $7 price target, stating approval is "more a question of timing." πŸ’Ž I'm holding this one as a medium-term position. Multiple FDA catalysts ahead. #OSTX #Biotech #Stocks #SmallCaps Not financial advice. For informational purposes only.
3
5
1,483
$VTGN πŸ‘€ πŸ”ΉοΈ Vistagen received the FDA's "Study May Proceed" letter for refisolone (its non-hormonal treatment for menopausal hot flashes) on April 22. πŸ”ΉοΈ Many investors are watching July 21, approximately 90 days later, for a potential update regarding the company's negotiations with Fuji Pharma. πŸ”ΉοΈ A definitive licensing agreement, if announced, could potentially include upfront cash, development and sales milestones, and future royalties. πŸ”ΉοΈ As of now, no definitive agreement has been announced publicly. πŸ‘€ Worth keeping on the watchlist to see how this develops. #VTGN #Biotech #Stocks #SmallCaps Not financial advice. For informational purposes only.
1
3
1,980
$PFSA 🚨πŸ”₯ πŸ”Ή Recent 1-for-25 reverse split has this setup gaining traction πŸ‘€ πŸ”Ή Post-split share count is now tiny β€” only around 530K shares outstanding ⚑ πŸ”Ή These reverse split / low-float names can move violently when volume finds them, just like traders saw with $NVVE πŸ“ˆ πŸ”Ή Not saying it is guaranteed, but the setup is exactly why $PFSA is on watch: tiny supply, momentum building, and traders hunting the next low-float runner πŸš€ πŸ”Ή Eyes on volume, halts, and whether this becomes the next sympathy move. #PFSA #NVVE #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
4
1,425
$VTGN πŸ’ŽπŸ§  πŸ”Ή I keep adding here. In my opinion, this is way oversold. πŸ”Ή VistaGen still has a late-stage CNS pipeline, with fasedienol targeting social anxiety disorder β€” a massive unmet need. πŸ‘€ πŸ”Ή The market punished the stock hard, but biotech can flip fast when sentiment changes, updates hit, or traders realize the risk/reward has shifted. πŸ“ˆ πŸ”Ή Not chasing green candles here β€” I’m building while fear is high and eyes are off the name. πŸ”₯ πŸ”Ή Patience required, but I still believe $VTGN has real rebound potential. #VTGN #Biotech #Stocks #SmallCaps #Momentum Not financial advice. For informational purposes only.
2
1
4
1,828
$PFSA 🚨 low float watch πŸ”Ή Profusa just completed a 1-for-25 reverse split, effective July 7 πŸ‘€ πŸ”Ή Post-split share count dropped from roughly 13.2M shares to only about 530K shares ⚑ πŸ”Ή That creates an extremely thin trading setup where volume can move this fast in either direction πŸ”₯ πŸ”Ή Company is a commercial-stage digital health name focused on continuous biochemistry monitoring technology 🧬 πŸ”Ή Recent reverse split + tiny post-split float = pure volatility setup. Watching for volume, momentum, and potential continuation πŸ“ˆ #PFSA #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
2
1,079
$FRGT πŸ’ŽπŸ™Œ πŸ”Ή Still holding. My thesis hasn't changed. πŸ”Ή With an effective tradable float of only around 500K shares, it doesn't take much sustained buying pressure to move this one. πŸ‘€ πŸ”Ή I believe this has the potential to make a run toward $10+ over time if momentum returns and the company continues to execute. πŸ“ˆ πŸ”Ή As always, I'll let the market decideβ€”but I'm staying patient and holding my position. πŸš€ #FRGT #Stocks #SmallCaps #LowFloat #Momentum Not financial advice. For informational purposes only.
1
1
1,091
$VEEE πŸš€πŸš€ +29% AH πŸ”Ή Twin Vee PowerCats seeing strong after-hours momentum with buyers stepping in πŸ‘€ πŸ”Ή The company designs and manufactures recreational and commercial power catamaran boats sold through a growing dealer network 🌊 πŸ”Ή No major company news appears to be driving today's move, making price action and volume the key story πŸ“ˆ πŸ”Ή Tiny market cap + low share count can create explosive moves when momentum traders pile in πŸ”₯ πŸ”Ή Watching premarket closely. If volume continues to build, traders will be looking for another leg higher tomorrow. πŸ‘€ #VEEE #Stocks #SmallCaps #MomentumNot financial advice. For informational purposes only.
4
1,667
$IOTR πŸš€ +65% AH πŸ”Ή iOThree just dropped a shareholder letter showing FY2026 revenue growth of 40% to $14.7M πŸ“ˆ πŸ”Ή Gross profit jumped 68.4% to $3.2M, with gross margin improving from 17.8% to 21.4% πŸ”₯ πŸ”Ή Company is focused on maritime digital solutions, edge computing, SaaS, satellite connectivity, AI analytics, carbon reporting + shipboard tech βš“πŸ€– πŸ”Ή CEO says demand across Asia remains healthy, especially Singapore and Taiwan, with Japan expansion targeted for early Q4 2026 🌏 πŸ”Ή Watching this one closely β€” tiny small-cap maritime tech name, strong AH momentum, real revenue growth, and a digital shipping/AI angle traders may chase πŸ‘€ #IOTR #Stocks #SmallCaps #AI #Maritime #Momentum Not financial advice. For informational purposes only.
1
1,555
$TC πŸš€ +32% AH πŸ”Ή Token Cat catching strong after-hours momentum πŸ‘€ πŸ”Ή No major fresh company PR showing yet β€” this looks like a pure momentum / low-float type move right now ⚑ πŸ”Ή Recent trading has been wild with huge volume spikes, big swings, and fast reversals πŸ“Š πŸ”Ή These thin ADR setups can move violently when volume hits β€” traders watching continuation vs. profit-taking tomorrow πŸ”₯ πŸ”Ή Eyes on volume, halts, and whether buyers can hold the AH move πŸ“ˆ #TC #Stocks #SmallCaps #Momentum Not financial advice. For informational purposes only.
1
1
1,237
$VTAK βœˆοΈπŸš€ +59% AH πŸ”Ή Catheter Precision subsidiary Flyte just announced a strategic partnership with LifeVac to equip every Cirrus Vision Jet with LifeVac anti-choking devices πŸ›©οΈ πŸ”Ή This adds medical emergency preparedness directly into the cabin β€” huge focus on passenger safety βš•οΈ πŸ”Ή Flyte is building around the Cirrus Vision Jet safety stack: CAPS whole-aircraft parachute, Safe Return Emergency Autoland, Garmin safety systems, carbon-fiber airframe + FADEC engine management πŸ”₯ πŸ”Ή LifeVac is FDA De Novo authorized as a second-line choking rescue device and has been credited with 6,200+ reported rescues worldwide πŸ‘€ πŸ”Ή AH momentum is strong here β€” traders watching volume, float, and whether this safety/aviation angle brings continuation tomorrow πŸ“ˆ #VTAK #Stocks #SmallCaps #Aviation #Momentum Not financial advice. For informational purposes only.
3
1,395
$FRGT πŸš›πŸ”₯ πŸ”Ή Freight Technologies ($FRGT) catching attention with strong AH momentum πŸ‘€ πŸ”Ή Extremely low float means it doesn't take much buying pressure to create explosive moves when volume pours in πŸ’₯ πŸ”Ή AI-powered logistics and cross-border freight platform focused on improving supply chain efficiency πŸ€–πŸ“¦ πŸ”Ή Low-float runners can move fast in both directions β€” volatility is part of the trade ⚠️ πŸ”Ή If momentum continues into tomorrow, this could be one to keep on the watchlist. Eyes on volume and whether buyers can sustain the breakout πŸš€ #FRGT #Stocks #LowFloat #Momentum #SmallCaps Not financial advice. For informational purposes only.
2
1,357